NeuroOne Medical Technologies Corporation (NMTC) AI Stock Analysis

NeuroOne Medical Technologies Corporation is a medical technology firm based in Eden Prairie, Minnesota, specializing in solutions for neurological disorders. Established in 2009, the company develops and commercializes thin film electrode technology used in continuous electroencephalogram and stereoelectroencephalography recording. Its technology supports spinal cord stimulation, brain stimulation, and ablation therapies. NeuroOne targets conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain from failed back surgeries. Additionally, the company collaborates with RBC Medical Innovations to develop a radio frequency ablation generator to further expand its therapeutic device offerings.

NeuroOne increased revenue from $178,146 in FY2021 to $12.1M in FY2025, reflecting a 5-year revenue CAGR of 44.4%. Fiscal year revenue rose 250.4% in FY2025, driven by expanding adoption, while gross margin improved to 67.3% from -54.9% in FY2021. Despite this top-line progress, operating margin was -34.9% and net income stood at -$3.6M in FY2025, though narrowing from -$12.3M in FY2024. For the trailing twelve months ended June 30, 2026, revenue totaled $12.5M, operating margin was -122.9%, and net profit margin was -59.7%. Latest quarterly revenue grew 16.3% year-over-year.

As of June 30, 2026, NeuroOne held $2.0M in cash and short-term investments and $73,320 in total debt, resulting in net cash of $2.0M. Shareholders' equity was $3.8M against total assets of $6.2M. The company maintains a current ratio of 2.84 and a debt-to-equity ratio of 0.02. In FY2025, operating cash flow was -$2.8M and free cash flow was -$2.9M. Cash deployment included $81,742 in capital expenditures and $124,617 in share buybacks, while the share count rose 240.3% over five years.

At $0.96 per share, NeuroOne has a market cap of $8.8M and an enterprise value of $10.4M. The stock trades at a price-to-sales multiple of 0.7x and an EV-to-revenue multiple of 1.1x, below the median of its US-listed Healthcare peers at 4.1x price-to-sales. Its price-to-book ratio is 3.3x. NeuroOne shares have lagged the broader market, dropping 81.4% over the past year and 94.7% over five years, compared to gains of 16.8% and 83.0% for the S&P 500 over the respective periods.

NeuroOne has a consensus positive view from covering analysts, with 2 Strong Buy ratings, 1 Buy rating, and zero Hold, Sell, or Strong Sell ratings. The average 12-month price target is $7.27, representing a 656.2% premium over the last close of $0.96. For the fiscal year ending September 30, 2026, analysts estimate revenue of $10.5M and an EPS of -$0.71. For the following fiscal year, 3 analysts project revenue to rise 26.6% to $13.3M with an EPS of -$0.63. The company beat EPS estimates in 2 of the past 4 quarters.

This page is an AI-written research summary of NeuroOne Medical Technologies Corporation (NMTC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NMTC income statement, NMTC balance sheet, NMTC key metrics, NMTC analyst forecast, NMTC chart. See the NMTC stock overview for the latest quote and news.